Resverlogix is a clinical biotechnology company that aims to improve and save the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease.
Company (IPO / Went public)
Phone: 403.254.9252
300, 4820 Richard Road SW
Calgary, T3E 6L1
Alberta, Canada
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Compositions and therapeutic methods for the treatment of complement-associated diseases | Sep 26, 2018 | Sep 15, 2020 | Patent |
Compounds for the prevention and treatment of cardiovascular diseases | Sep 20, 2017 | Jan 14, 2020 | Patent |
Novel anti-inflammatory agents | Nov 16, 2015 | Nov 20, 2018 | Patent |
Compositions and therapeutic methods for the treatment of complement-associated diseases | Mar 10, 2016 | Oct 30, 2018 | Patent |
Pharmaceutical compositions for substituted quinazolinones | Jan 18, 2017 | Jul 10, 2018 | Patent |